Keyphrases
National Institutes of Health
100%
Golimumab
100%
Ankylosing Spondylitis
100%
Single Technology Appraisal
100%
Clinical Excellence
100%
Etanercept
77%
Tumour Necrosis Factor Inhibitor (TNFi)
77%
Evidence Review
66%
Mixed Treatment Comparison
55%
Adalimumab
44%
Cost-effectiveness Analysis
33%
Adverse Events
22%
Relative Risk
22%
Treatment Discontinuation
22%
Incremental Cost-effectiveness Ratio
22%
Conventional Care
22%
Randomized Controlled Trial
11%
Treatment Options
11%
Treatment Effect
11%
Placebo
11%
Placebo-controlled
11%
Tumor Necrosis Factor-α
11%
Functional Capacity
11%
Process of Care
11%
Cost-effectiveness
11%
Comparative Analysis
11%
Adverse Effects
11%
Health-related Quality of Life
11%
Relative Effectiveness
11%
Cost-effective Treatment
11%
Disease Progression
11%
Active Disease
11%
Disease Activity
11%
Index Score
11%
Clinical Efficacy
11%
Conventional Treatment
11%
Group Analysis
11%
Pounding
11%
Appraisal Processes
11%
Conventional Therapy
11%
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
11%
Merck
11%
Inhibitor Agent
11%
Methods Guidance
11%
Credible Interval
11%
Sequencing Problem
11%
Technology Assessment
11%
Simponi
11%
Guidance Technology
11%
Head-to-head Trials
11%
Comparison Estimate
11%
Handling Uncertainty
11%
Treatment-related Quality of Life
11%
Intolerant
11%
Trial Data
11%
Response Proportions
11%
INIS
appraisal
100%
tumor necrosis factor
100%
ankylosing spondylitis
100%
comparative evaluations
87%
reviews
75%
diseases
50%
cost
50%
risks
37%
manufacturers
37%
cost effectiveness analysis
37%
data
25%
therapy
25%
patients
12%
quality of life
12%
populations
12%
exceptions
12%
capacity
12%
cea
12%
Nursing and Health Professions
Ankylosing Spondylitis
100%
Golimumab
100%
Tumor Necrosis Factor Inhibitor
70%
Etanercept
70%
Cost Effectiveness Analysis
40%
Adalimumab
40%
Adverse Event
20%
Incremental Cost-Effectiveness Ratio
20%
Placebo
20%
Base
10%
Quality of Life
10%
Disease Exacerbation
10%
Disease Activity
10%
Functional Status
10%
Tumor Necrosis Factor
10%
Bath Ankylosing Spondylitis Disease Activity Index
10%
Carcinoembryonic Antigen
10%
Diseases
10%
Pharmacology, Toxicology and Pharmaceutical Science
Ankylosing Spondylitis
100%
Golimumab
100%
Tumor Necrosis Factor Inhibitor
70%
Etanercept
70%
Adalimumab
40%
Placebo
20%
Adverse Event
20%
Disease Activity
20%
Randomized Controlled Trial
10%
Tumor Necrosis Factor
10%
Functional Status
10%
Base
10%
Disease Exacerbation
10%
Carcinoembryonic Antigen
10%
Diseases
10%
Immunology and Microbiology
Ankylosing Spondylitis
100%
Golimumab
100%
TNF Inhibitor
70%
Etanercept
70%
Adalimumab
40%
Functional Status
10%
Tumor Necrosis Factor Alpha
10%
Carcinoembryonic Antigen
10%
Agricultural and Biological Sciences
Tumor Necrosis Factor
100%
Tumor Necrosis Factor Alpha
100%
Adalimumab
50%
Placebo
25%
Relative Risk
25%
Quality of Life
12%
Adverse Effects
12%
Carcinoembryonic Antigen
12%
Veterinary Science and Veterinary Medicine
Ankylosing Spondylitis
100%
Neoplasm
100%